【摘要】 目的探讨切除修复交叉互补基因1(ERCC1)表达与Ⅱ～ⅢA期鼻咽癌顺铂同期放化疗疗效的关系。方法78例Ⅱ～ⅢA期鼻咽癌患者接受顺铂同期放化疗,检测鼻咽癌组织ERCC1蛋白和mRNA表达水平,分析ERCC1表达与疗效的关系。结果 ERCC1蛋白阳性表达率为46.15%,mRNA水平为0.456～1.412。78例患者中,完全缓解63例,部分缓解7例,病情稳定4例,疾病进展4例,有效率为89.74%,疾病控制率为94.87%。ERCC1蛋白阳性表达患者有效率为80.56%,低于ERCC1蛋白阴性表达患者的97.62%(P<0.05)。ERCC1mRNA低表达患者有效率为97.56%,高于ERCC1 mRNA高表达患者的81.08%(P<0.05)。78例患者1年生存率为98.72%,3年生存率为93.59%,5年生存率为91.03%。ERCC1蛋白阳性表达和阴性表达患者生存率比较无统计学差异(P>0.05),ERCC1mRNA高表达患者和低表达患者生存率比较亦无统计学差异(P>0.05)。结论 ERCC1的表达与Ⅱ～ⅢA期鼻咽癌患者顺铂同期放化疗疗效有关,但与患者生存率无关。更多还原

【Abstract】 Objective To investigate the relationship of excision repair cross complementary gene 1(ERCC1)expression and the efficacy of cisplatin concurrent radiochemotherapy for the patients with stageⅡ-ⅢA nasopharyngeal carcinoma.Methods A total of 78 cases with stageⅡ-ⅢA nasopharyngeal carcinoma was treated with cisplatin concurrent radiochemotherapy.The protein and mRNA expressions of ERCC1 were detected.The relationship of ERCC1 and the efficacy of cisplatin concurrent radiochemotherapy was analyzed.Results The protein positive expression of ERCC1 was46.15% and mRNA level was 0.456-1.412.Of 78 cases,63 cases were complete remission,7 cases were partial remission,4 cases were stable disease and 4 cases were progressive disease.The effectiveness rate and disease control rate were 89.74% and 94.87%,respectively.The effectiveness rate of the patients with protein positive expression and those with protein negative expression was significantly different(80.56% vs.97.62%)(P<0.05).The effectiveness rate of the patients with lower mRNA expression and those with higher mRNA expression was significantly different(97.56%vs.81.08%)(P<0.05).The 1-year,3-year and 5-year survival rates were 98.72%,93.59%and 91.03%,respectively,which were not related to the protein and mRNA expressions of ERCC1(P>0.05).Conclusion ERCC1 expression is related to the efficacy of cisplatin concurrent radiochemotherapy in the patients with stageⅡ-ⅢA nasopharyngeal carcinoma,which is not related to survival rate.更多还原